title: Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages.
abstract: In 1984, all non-immune children under the age of 5 years in the Gambian villages of Keneba and Manduar were vaccinated against hepatitis B virus (HBV). All children born in these villages since 1984 have been vaccinated in infancy. Despite a rapid fall in antibody concentrations, vaccine efficacy against HBV infection and chronic carriage of HBsAg has increased with time. Overall, vaccine efficacies in 1993 against HBV infection and chronic HBsAg carriage were 94.7% (95% Cl 93.0-96.0) and 95.3% (91.0-97.5), respectively. Breakthrough infections in vaccinated children largely originate from chronic HBsAg carriers. Thus, we tested 261 chronic carriers for HBV DNA and e antigen. The prevalence of these markers of infectivity, and the amount of HBV DNA, decreased greatly with age. Detailed studies of breakthrough infections over two 4-year periods revealed that in the second period there were fewer than half the expected numbers of infections. Our findings suggest that in Keneba and Manduar long-term vaccination is progressively decreasing HBV transmission by chronic carriers, since their infectivity diminishes with time.
authors.affiliation: Medical Research Council Laboratories, Banjul, The Gambia.
authors.forename: H C
authors.initials: HC
authors.lastname: Whittle
authors.forename: N
authors.initials: N
authors.lastname: Maine
authors.forename: J
authors.initials: J
authors.lastname: Pilkington
authors.forename: M
authors.initials: M
authors.lastname: Mendy
authors.forename: M
authors.initials: M
authors.lastname: Fortuin
authors.forename: J
authors.initials: J
authors.lastname: Bunn
authors.forename: L
authors.initials: L
authors.lastname: Allison
authors.forename: C
authors.initials: C
authors.lastname: Howard
authors.forename: A
authors.initials: A
authors.lastname: Hall
mesh_terms: D000293:Adolescent; D000328:Adult; D002353:Carrier State / Q000517:prevention & control; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D005260:Female; D005714:Gambia / Q000453:epidemiology; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D015995:Prevalence
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines